Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.
Edwards
H S
HS
MRC Radiobiology Unit, Chilton, Didcot, UK.
Bremner
J C
JC
Stratford
I J
IJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009368:Neoplasm Transplantation; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000628:therapy*; D000077704:Tirapazamine; D014227:Triazines / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D005419:Flavonoids; D008937:Mitomycins; D014227:Triazines; D014409:Tumor Necrosis Factor-alpha; D000077704:Tirapazamine; D016685:Mitomycin; C049328:flavone acetic acid; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole